



**The Clatterbridge
Cancer Centre**
NHS Foundation Trust

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Date: 20 January 2020

Re: Freedom of Information Request
Ref: 370 - 2019

Thank you for your email dated the 20th December 2019, requesting information regarding the treatment of Lung and Melanoma patients.

The information that you require is as follows:

Please note in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown below:

1. How many melanoma patients currently undergoing treatment are BRAF+ ?

Between 1st Oct 2019 and 31st Dec 2019 we treated 180 Melanoma patients with SACT, out of which BRAF status was recorded follows:

BRAF V600	Number
Positive	41
Negative	62
Not known/Not stated	139

2. In the past 3 months (Between 1st Oct 2019 and 31st Dec 2019), how many melanoma patients were treated with the following:

Bevacizumab = 0 patients

Cobimetinib = 0 patients

Dabrafenib = Exempt under S.40

Dabrafenib AND trametinib = 38 patients

Dacarbazine = 0 patients

Encorafenib AND binimetinib = 0 patients

Ipilimumab = 6 patients

Ipilimumab AND Nivolumab = Exempt under S.40

Nivolumab = 39 patients

Pembrolizumab = 87 patients

Trametinib = Exempt under S.40

Vemurafenib = 0 patients

Vemurafenib AND Cobimetinib = 0 patients

Other active systemic anti-cancer therapy = 15 patients on a clinical trial

Palliative care = Exempt under S.40

In the past 3 months how many patients were seen who had stage III resectable melanoma

16 patients registered at CCC between 1st Oct 2019 and 31st Dec 2019 had Stage III melanoma. We do not record if it was resectable

Of all stage III patients seen, how many received a complete resection?

We do not record this information

Of all stage III patients seen, how many were stage III a ?

Exempt under S.40

3. Within your health trust how many patients are currently [within the past 3 months] being treated with the following for Non-small cell lung cancer (NSCLC)

Between 1st Oct 2019 and 31st Dec 2019:

Afatinib = 37 patients

Alectinib = 12 patients

Atezolizumab + bevacizumab + carboplatin + paclitaxel = Exempt under S.40

Atezolizumab mono = 34 patients

Bevacizumab = 0 patients

Brigatinib = Exempt under S.40

Ceritinib = Exempt under S.40

Crizotinib = Exempt under S.40

Dacomitinib = Exempt under S.40

Docetaxel monotherapy = Exempt under S.40

Durvalumab = 7 patients

Erlotinib = 18 patients

Gefitinib = 8 patients

Gemcitabine = 0 patients

Necitumumab = 0 patients

Nintedanib with docetaxel = Exempt under S.40

Nivolumab = 9 patients

Osimertinib = 14 patients

Paclitaxel = 0 patients

Pembrolizumab chemo in combination = 28 patients

Pembrolizumab monotherapy = 121 patients

Pemetrexed = 11 patients

Pemetrexed with carboplatin = 25 patients

Pemetrexed with cisplatin = Exempt under S.40

Ramucirumab = 0 patients

Vinorelbine and cisplatin / carboplatin = 65 patients

Other active systemic anti-cancer therapy = 104 patients

Palliative care = Out of the patients registered at CCC between 1st Oct 2019 and 31st Dec 2019 – 28 had specialist palliative care recorded as first intervention

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.